Figure 2.
MMR rate difference (95% CI) between treatment at week 156 from subgroup analyses. ∗Patients with T315I and V299L BCR::ABL1 mutations or a nonevaluable mutation assessment were excluded from the subgroup analysis. CRF, case report form.
MMR rate difference (95% CI) between treatment at week 156 from subgroup analyses. ∗Patients with T315I and V299L BCR::ABL1 mutations or a nonevaluable mutation assessment were excluded from the subgroup analysis. CRF, case report form.
